Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 358

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 358
---
                                             ( 292)        ( 503)        ( 795)        ( 248)        ( 623)        ( 300)      ( 1,627)  
  Impairment of intangible assets (4)                                               —             —                           —                                            
  Total net operating expenses                                                                                                                                             

(1) The Company subcontracts a significant part of its preclinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. Associated costs are recorded in subcontracting on the basis of the level of completion of the clinical trials.

F-79

(2) Non-scientific advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support.

(3) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.

(4) Following the Company's decision in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well as of June 30, 2022), the rights relating to the intangible asset have been fully impaired for their net book value on the date of the decision, i. e. € 41,000

                              Year ended December 31,                                                                                              
                                                 2022                                2023                                2024                      
  (in thousands of euro)          Deloitte & Associés      Total      Deloitte & Associés      Total      Deloitte & Associés      PwC      Total  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Audit fees                                      855      855                        725        725                      523      475      998    
  Non-audit fees                                  248      248                        213        213                      208      100      308    
  Total                                                                               938        938                      731      575             

* Non-audit fees: these fees correspond to services performed by the auditors related to the production of certification in the context of the declaration of expenses for the obtention of grants; to the verification report of social and environmental information, special reports within the framework of operations on